Mycophenolate Add-on Therapy Is Effective in Severe IgA Nephropathy

BACKGROUND: IgA Nephropathy (IgAN) is the most common primary glomerulonephritis. There is limited evidence on the use of mycophenolate mofetil (MMF) in IgAN in non-Asian populations. This study evaluates the efficacy of MMF in IgAN. METHODS: Retrospective cohort study of patients with biopsy-confirmed IgAN between 2013 and 2024, with at least 6 months of follow-up. Patients were classified into three groups based on the treatment received in the first 6 months after diagnosis: (1) Supportive care, (2) Corticosteroids, (3) MMF add-on. Data were collected at baseline, 3, 6, 12, and 24 months. Changes in estimated glomerular filtration rate (eGFR), urinary protein-to-creatinine ratio (UPCR) and hematuria were assessed. The composite outcome included eGFR <15 mL/min/1.73 m2, kidney replacement therapy, the need for additional immunosuppressive therapy, kidney transplantation, or death assessed over a median follow-up of 43 months. Outcomes evaluated included eGFR below 15 ml/min/1.73m2, initiation of dialysis, transplantation, another immunosuppressant or death. RESULTS: Sixty-four patients were included: 19 MMF add-on, 14 Corticosteroids, and 31 Supportive care. Patients in the MMF add-on and corticosteroid groups had a more severe clinical profile compared to the Supportive care group. At 24 months, the MMF add-on and corticosteroids group showed a greater UPCR reduction compared to the Supportive care group (reduction of 57% p = 0.02 for both groups). In the MMF add-on group, hematuria reduction was significantly greater and renal function improved from the third month. CONCLUSIONS: Patients treated with MMF had similar outcomes to the supportive care group, despite having significantly more severe disease at baseline. These results suggest that MMF add-on could be a potential treatment for non-Asian patients with severe IgAN.

Authors

Institutions

Publication Details

Journal
Kidney360
Published
2026-11-18
DOI
https://doi.org/10.34067/kid.0000001443
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mycophenolate Add-on Therapy Is Effective in Severe IgA Nephropathy

Sheila Bermejo, Laia Sans, Ehimy Marcela Suárez Barajas, Oriol Bestard et al.
2 links
Kidney360
Renal Diseases and Glomerulopathies
article

Mycophenolate Add-on Therapy Is Effective in Severe IgA Nephropathy

Sheila Bermejo, Laia Sans, Ehimy Marcela Suárez Barajas, Oriol Bestard, Juan Carlos León Román, Natalia Ramos-Terrades, María José Soler, Federico Yandián, Alejandra Gabaldón, Sara Núñez-Delgado, Marina López-Martínez, Efrain Tatis, Tiffany Alvarez, Irene Agraz
article en

Abstract

BACKGROUND: IgA Nephropathy (IgAN) is the most common primary glomerulonephritis. There is limited evidence on the use of mycophenolate mofetil (MMF) in IgAN in non-Asian populations. This study evaluates the efficacy of MMF in IgAN. METHODS: Retrospective cohort study of patients with biopsy-confirmed IgAN between 2013 and 2024, with at least 6 months of follow-up. Patients were classified into three groups based on the treatment received in the first 6 months after diagnosis: (1) Supportive care, (2) Corticosteroids, (3) MMF add-on. Data were collected at baseline, 3, 6, 12, and 24 months. Changes in estimated glomerular filtration rate (eGFR), urinary protein-to-creatinine ratio (UPCR) and hematuria were assessed. The composite outcome included eGFR <15 mL/min/1.73 m2, kidney replacement therapy, the need for additional immunosuppressive therapy, kidney transplantation, or death assessed over a median follow-up of 43 months. Outcomes evaluated included eGFR below 15 ml/min/1.73m2, initiation of dialysis, transplantation, another immunosuppressant or death. RESULTS: Sixty-four patients were included: 19 MMF add-on, 14 Corticosteroids, and 31 Supportive care. Patients in the MMF add-on and corticosteroid groups had a more severe clinical profile compared to the Supportive care group. At 24 months, the MMF add-on and corticosteroids group showed a greater UPCR reduction compared to the Supportive care group (reduction of 57% p = 0.02 for both groups). In the MMF add-on group, hematuria reduction was significantly greater and renal function improved from the third month. CONCLUSIONS: Patients treated with MMF had similar outcomes to the supportive care group, despite having significantly more severe disease at baseline. These results suggest that MMF add-on could be a potential treatment for non-Asian patients with severe IgAN.

Kidney360
Hebron University (PS), Vall d'Hebron Institut de Recerca (ES), Vall d'Hebron Hospital Universitari (ES), Sistema Nacional de Salud (ES)
Good health and well-being
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon